Sussman M A, Lim H W, Gude N, Taigen T, Olson E N, Robbins J, Colbert M C, Gualberto A, Wieczorek D F, Molkentin J D
Division of Molecular Cardiovascular Biology, Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.
Science. 1998 Sep 11;281(5383):1690-3. doi: 10.1126/science.281.5383.1690.
Hypertrophic cardiomyopathy (HCM) is an inherited form of heart disease that affects 1 in 500 individuals. Here it is shown that calcineurin, a calcium-regulated phosphatase, plays a critical role in the pathogenesis of HCM. Administration of the calcineurin inhibitors cyclosporin and FK506 prevented disease in mice that were genetically predisposed to develop HCM as a result of aberrant expression of tropomodulin, myosin light chain-2, or fetal beta-tropomyosin in the heart. Cyclosporin had a similar effect in a rat model of pressure-overload hypertrophy. These results suggest that calcineurin inhibitors merit investigation as potential therapeutics for certain forms of human heart disease.
肥厚型心肌病(HCM)是一种遗传性心脏病,每500人中就有1人受其影响。本文表明,钙调神经磷酸酶(一种受钙调节的磷酸酶)在HCM的发病机制中起关键作用。给予钙调神经磷酸酶抑制剂环孢素和FK506可预防因心脏中原肌球蛋白、肌球蛋白轻链-2或胎儿β-原肌球蛋白异常表达而具有HCM遗传易感性的小鼠发病。环孢素在压力超负荷肥大的大鼠模型中也有类似作用。这些结果表明,钙调神经磷酸酶抑制剂作为某些形式人类心脏病的潜在治疗方法值得研究。